1-((Ξ)-2-bromo-propionyl)-L-proline | 115116-62-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-((Ξ)-2-bromo-propionyl)-L-proline
• 英文别名: 1-((Ξ)-2-Brom-propionyl)-L-prolin；(2S)-1-(2-bromopropanoyl)pyrrolidine-2-carboxylic acid
• CAS: 115116-62-6
• 化学式: C₈H₁₂BrNO₃
• 分子量: 250.092
• InChiKey: KPPCXGFDXLCBCU-GDVGLLTNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-((Ξ)-2-bromo-propionyl)-L-proline 在 ammonium hydroxide 作用下， 生成 1-Ξ-lactoyl-L-proline amide
  参考文献：
  名称：

  Abderhalden; Zumstein, Fermentforschung, 1930, vol. 12, p. 1,10

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴丙酰溴 、 L-脯氨酸 在 sodium hydroxide 作用下， 生成 1-((Ξ)-2-bromo-propionyl)-L-proline
  参考文献：
  名称：

  Abderhalden; Nuessler, Biochemische Zeitschrift, 1933, vol. 266, p. 216,219

  摘要：

  DOI：

文献信息

• Ace-inhibitors having antioxidant and no-donor activity
  申请人：Haj-Yehia Ibrahim Abdullah

  公开号：US20060166894A1

  公开（公告）日：2006-07-27

  Multifonctional ACE inhibitor compounds are provided, that combine ACE-inhibiting activity with capability to scavenge superoxide and other reactive oxygen species, and that may further function as nitric oxide donors. The compounds are useful for preventing or treating various disorders, including cardiovascular, and diabetes associated disorders.

  提供了多功能ACE抑制剂化合物，其将ACE抑制活性与清除超氧化物和其他反应性氧化物的能力相结合，并可能进一步作为一氧化氮供体发挥作用。这些化合物可用于预防或治疗各种疾病，包括心血管和与糖尿病相关的疾病。
• New compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0237239A2

  公开（公告）日：1987-09-16

  The present invention is concerned with compounds of formula (I), physiologically acceptable salts thereof, formulations containing them, their preparation and their use in medicine. In formula (I) A is a group of formula -Qk-(NQ1)m-(CH2)n-, where k and m are Independently selected from 0 and 1, provided that m can only be 0 when k is 0, n is from 1 to 6, Q1 is hydrogen or C1-4 alkyl, and Q is selected from -CO-, -CH2-, -CH2CO- and -QCH2CO-, and any of the -(CH2)n- groups are independently optionally substituted by one or two C1-4 alkyl groups; B is group of formula -R1-C(Q2) (OH)-C(Q3) (Q4)-NQ5-R2, where R' is a bond or -OC(Q6) (Q7)- R2 is hydrogen or C1-6 alkyl, and Q2-Q7 are independently hydrogen, C1-4 alkyl, or a group of formula -(C(Q8)(Q9))×Ph, in which x is 1 or 2, Ph is a phenyl group optionally substituted by one or more groups Independently selected from hydroxy, C1-4 alkyl and C1-4 alkoxy, and Q8 and Q9 are independently hydrogen or C1-4 alkyl; E and Z are independently selected from carboxyl and carboxyl derivatives; D is hydrogen or a saturated or unsaturated C1-6 aliphatic substituent optionally substituted by an amino group; G1, G2 and G3 are independently selected from hydrogen and C1-4 alkyl; (X) is a mono-, bi-, or tri-cyclic aromatic ring system optionally containing one or more heteroatoms; and (Y) is a mono- or bi-cyclic nitrogen-containing ring system (attached to -CO-C(D)(G3)- by said nitrogen atom) optionally containing one or more other heteroatoms and optionally substituted by one or more substituents independently selected from C1-6 alkyl and aryl (e.g. phenyl), or (Y) is a nitrogen atom attached to E directly by a bond or indirectly by a C1-4 alkylene moiety and also attached to a C5-7 cycloalkyl group; in either case (Y) may optionally be linked by a C3-5 alkylene bridge to G3 or D to form a closed ring; and physiologically acceptable salts thereof; with the proviso that: when, in the definition of A, k and m are both 0 or both 1 and 0 is a -CO- group, and, in the definition of B, R' is a group of formula -OC(Q6)(Q7)- as hereinbefore defined and R2 is a C1-6 alkyl group; D is hydrogen or a C1-6 alkyl group; (X) is a benzene ring or a naphthyl or indolyl ring system, any of which is optionally substituted in any position by one or more substituents independently selected from C1-4 alkyl (itself optionally substituted by one or more halogen atoms), C1-4 alkoxy, halo, nitro, amino, carboxyl, C1-4 alkoxycarbonyl and hydroxy, then (Y) is not a pyrrolidinyl, oxazolidinyl, or thiazolidinyl ring, or a ring system selected from indolinyl, quinolinyl and tetrahydroquinolinyl.

  本发明涉及式（I）化合物、其生理上可接受的盐、含有它们的制剂、它们的制备及其在医学中的应用。 在式 (I) 中 A 是式-Qk-(NQ1)m-(CH2)n-的基团，其中 k 和 m 独立地选自 0 和 1，条件是当 k 为 0 时 m 只能为 0，n 为 1 至 6，Q1 为氢或 C1-4 烷基，Q 选自 -CO-、-CH2-、-CH2CO- 和 -QCH2CO-，且任一-(CH2)n-基团独立地任选被一个或两个 C1-4 烷基取代； B 是式-R1-C(Q2) (OH)-C(Q3) (Q4)-NQ5-R2 的基团，其中 R' 是键或-OC(Q6) (Q7)-R2 是氢或 C1-6 烷基，且 Q2-Q7 独立地是氢、C1-4 烷基或式-(C(Q8)(Q9))×Ph.的基团、其中 x 为 1 或 2，Ph 为可选被一个或多个独立选自羟基、C1-4 烷基和 C1-4 烷氧基的基团取代的苯基，Q8 和 Q9 独立为氢或 C1-4 烷基； E 和 Z 独立选自羧基和羧基衍生物； D 是氢或任选被氨基取代的饱和或不饱和 C1-6 脂肪族取代基； G1、G2 和 G3 独立选自氢和 C1-4 烷基； (X) 是单环、双环或三环芳环系统，可选含有一个或多个杂原子；以及 (Y) 是单环或双环含氮环系（通过所述氮原子连接到 -CO-C(D)(G3)-），可选地含有一个或多个其他杂原子，并可选地被一个或多个取代基取代，这些取代基独立选自 C1-6 烷基和芳基（例如：苯基），或被一个或多个取代基取代。例如苯基），或（Y）是通过键直接连接到 E 或通过 C1-4 亚烷基间接连接到 C5-7 环烷基的氮原子；在任一情况下，（Y）可选择通过 C3-5 亚烷基桥连接到 G3 或 D 形成闭环； 及其生理上可接受的盐类； 但条件是 当在 A 的定义中，k 和 m 均为 0 或均为 1 且 0 为-CO-基团时，以及在 B 的定义中，R'为如前定义的式-OC(Q6)(Q7)-基团且 R2 为 C1-6 烷基基团时； D 是氢或 C1-6 烷基； (X) 是苯环或萘基或吲哚基环系，其中任一环系在任一位置任选被独立选自 C1-4 烷基（本身任选被一个或多个卤原子取代）、C1-4 烷氧基、卤代、硝基、氨基、羧基、C1-4 烷氧羰基和羟基的一个或多个取代基取代、 则 (Y) 不是吡咯烷基、噁唑烷基或噻唑烷基环，也不是选自吲哚啉基、喹啉基和四氢喹啉基的环系。
• Abderhalden, Fermentforschung, 1935, vol. 14, p. 128
  作者：Abderhalden

  DOI：——

  日期：——
• ACE-INHIBITORS HAVING ANTIOXIDANT AND NO-DONOR ACTIVITY
  申请人：YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

  公开号：EP1578413A2

  公开（公告）日：2005-09-28
• [EN] ACE-INHIBITORS HAVING ANTIOXIDANT AND NO-DONOR ACTIVITY<br/>[FR] INHIBITEURS D'ENZYME DE CONVERSION DE L'ANGIOTENSINE POSSEDANT UNE ACTIVITE ANTIOXYDANTE ET DE DONNEUR D'OXYDE NITRIQUE (NO)
  申请人：YISSUM RES DEV CO

  公开号：WO2004050084A2

  公开（公告）日：2004-06-17

  Multifonctional ACE inhibitor compounds are provided, that combine ACE-inhibiting activity with capability to scavenge superoxide and other reactive oxygen species, and that may further function as nitric oxide donors. The compounds are useful for preventing or treating various disorders, including cardiovascular, and diabetes associated disorders.